Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 8/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 5/20 | 0.72 |
| ▸ | LMNA | P02545 | 2/20 | 0.72 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.72 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.72 |
| ▸ | ACHE | P22303 | 2/20 | 0.72 |
| ▸ | PDE4A | P27815 | 2/20 | 0.72 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.72 |
| ▸ | USP2 | O75604 | 1/20 | 0.72 |
| ▸ | TSHR | P16473 | 1/20 | 0.72 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.72 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.72 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.72 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.72 |
| ▸ | ESR1 | P03372 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5424162 | 0.96 | TNF (1.00) | TNFADORA2BLMNACYP1A2NFKB1 | |
| SCHEMBL17682325 | 0.89 | TNF (0.80) | TNFADORA2BLMNACYP1A2NFKB1 | |
| SCHEMBL8644270 | 0.88 | TNF (0.79) | TNFADORA2BLMNACYP1A2NFKB1 | |
| SCHEMBL17682215 | 0.87 | TNF (0.77) | TNFADORA2BLMNACYP1A2NFKB1 | |
| SCHEMBL6384593 | 0.86 | TNF (1.00) | TNFADORA2BLMNACYP1A2NFKB1 | |
| Pentoxifylline SCHEMBL27256824 | 0.85 | TNF (0.86) | TNFADORA2BLMNACYP1A2NFKB1 | |
| SCHEMBL16730548 | 0.84 | ADORA2B (0.77) | TNFADORA2BLMNACYP1A2NFKB1 | |
| Pentoxifylline SCHEMBL3986204 | 0.84 | ADORA2B (1.00) | TNFADORA2BLMNACYP1A2NFKB1 | |
| SCHEMBL5412111 | 0.84 | ADORA2B (0.81) | TNFADORA2BLMNACYP1A2NFKB1 | |
| SCHEMBL18255987 | 0.84 | ADORA2B (0.81) | TNFADORA2BLMNACYP1A2NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111233863-B | Hydroxyl purine compound and application thereof | 广东众生睿创生物科技有限公司 | 2022-10-25 | — | — | CN | disclosed |
| US-RE49128-E1 | Hydroxyl purine compounds and applications thereof | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2022-07-12 | — | — | US | disclosed |
| US-RE49128-E1 | Hydroxyl purine compounds and applications thereof | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2022-07-12 | — | — | US | disclosed |
| EP-3205652-B1 | HYDROXYL PURINE COMPOUNDS AND APPLICATIONS THEREOF | GUANGDONG RAYNOVENT BIOTECH CO LTD (CN) | 2022-03-09 | — | — | EP | disclosed |
| CN-108348525-B | Medical application of hydroxyl purine compound | 广东众生睿创生物科技有限公司 | 2021-09-10 | — | — | CN | disclosed |
| CN-111233863-A | Hydroxyl purine compound and application thereof | 广东众生睿创生物科技有限公司 | 2020-06-05 | — | — | CN | disclosed |
| CN-105566324-B | Hydroxyl purine compound and application thereof | 广东众生睿创生物科技有限公司 | 2020-04-03 | — | — | CN | disclosed |
| US-10098885-B2 | Hydroxyl purine compounds and applications thereof | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2018-10-16 | — | — | US | disclosed |
| US-20170326149-A1 | HYDROXYL PURINE COMPOUNDS AND APPLICATIONS THEREOF | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2017-11-16 | — | — | US | disclosed |
| US-20170326149-A1 | HYDROXYL PURINE COMPOUNDS AND APPLICATIONS THEREOF | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2017-11-16 | — | — | US | disclosed |
| US-20170326149-A1 | HYDROXYL PURINE COMPOUNDS AND APPLICATIONS THEREOF | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2017-11-16 | — | — | US | disclosed |
| EP-3205652-A1 | HYDROXYL PURINE COMPOUNDS AND APPLICATIONS THEREOF | Medshine Discovery Inc. (CN) | 2017-08-16 | — | — | EP | disclosed |
| EP-3205652-A1 | HYDROXYL PURINE COMPOUNDS AND APPLICATIONS THEREOF | Medshine Discovery Inc. (CN) | 2017-08-16 | — | — | EP | disclosed |
| WO-2017071606-A1 | MEDICAL USE OF HYDROXYL PURINE COMPOUND | 南京明德新药研发股份有限公司 | 2017-05-04 | — | — | WO | disclosed |
| WO-2016054971-A1 | HYDROXYL PURINE COMPOUNDS AND APPLICATIONS THEREOF | 南京明德新药研发股份有限公司 | 2016-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170326149-A1 | HYDROXYL PURINE COMPOUNDS AND APPLICATIONS THEREOF | PNP, PDE2A, PDE7A | TNF 45/4885ADORA2B 116/4885LMNA 2616/4885 |
| US-10098885-B2 | Hydroxyl purine compounds and applications thereof | PNP, PDE2A, PDE7A | TNF 45/4885ADORA2B 116/4885LMNA 2616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.